SBOT - Stellar Biotechnologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Stellar Biotechnologies, Inc.

332 East Scott Street
Port Hueneme, CA 93041
United States
805-488-2800
http://www.stellarbiotechnologies.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Mr. Frank R. OakesChairman, Pres & CEO429.84kN/A1950
Ms. Kathi Niffenegger CPACFO & Corp. Sec.262.81kN/A1957
Dr. Gregory T. BaxterExec. VP of Corp. Devel.N/AN/A1959
Mr. Gary KoppenjanSr. Director of Investor Relations & CommunicationsN/AN/AN/A
Brando LincicumExec. Director of Aquaculture and Facility OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Corporate Governance

Stellar Biotechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.